| 名称 | 持有数量(万股) | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 香港中央结算有限公司 | 502.98 | 0.86 | 退出 | | 华夏中证1000ETF | 360.35 | 0.62 | 退出 | | 孙少杰 | 295.00 | 0.51 | 退出 | | 李方进 | 287.64 | 0.49 | 退出 | | 广发中证1000ETF | 235.97 | 0.40 | 退出 | | 中国国际金融股份有限公司 | 170.75 | 0.29 | 退出 | | 陈俊廷 | 162.66 | 0.28 | 退出 | | MORGAN STANLEY & CO. INTERNATIONAL PLC. | 154.47 | 0.27 | 退出 | | 华泰证券股份有限公司 | 147.61 | 0.25 | 退出 | 三、分红送配方案情况 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 82214.42万股，累计占流通股比： 58.55%，较上期变化： 792 ...

东方通连跌7天，南方基金旗下1只基金位列前十大股东 3月26日，东方通连续7个交易日下跌，区间累计跌幅-13.31%。北京东方通科技股份有限公司(股票代码:300379.SZ),中国中间件的开拓者和领导者,大安全及 行业信息化解决方案提供商,以"安全+"、"数据+"和"智慧+"三大产品体系为基础,为客户提供优质的中间件、网络信息安全及行业数字化产品、解决方案及服 务支撑。 财报显示，南方基金旗下南方中证1000ETF为东方通前十大股东，去年三季度增持。今年以来收益率5.97%，同类排名807(总3440)。 | | | 南方中证1000ETF基金经理为崔蕾。 简历显示，崔蕾女士:中国国籍,康奈尔大学金融工程硕士,金融风险管理师(FRM),特许金融分析师(CFA),具有基金从业资格。2015年2月加入南方基金,历任数 量化投资部助理研究员、研究员,指数投资部研究员;2019年7月12日至2021年4月23日,任南方小康ETF、南方小康ETF联接基金经理;2019年6月28日至2022年2 月18日,任大数据300基金经理;2020年3月26日至2023年3月27日,任南方粤港澳大湾区联接基金经理;2022年12 ...

Group 1 - China Aluminum Corporation's stock dropped by 2.41% on March 26 [1] - The company was established in 2001 and is primarily engaged in non-ferrous metal smelting and rolling [1] - The registered capital of China Aluminum is approximately 17.02 billion RMB [1] Group 2 - Huatai-PineBridge Fund's Huatai-PineBridge CSI 300 ETF is among the top ten shareholders of China Aluminum and reduced its holdings in the last quarter of the previous year [1] - The fund has a year-to-date return of 0.12%, ranking 2541 out of 3440 in its category [2] Group 3 - The fund manager of Huatai-PineBridge CSI 300 ETF is Liu Jun, who has extensive experience in fund management since joining Huatai-PineBridge in 2004 [3][4] - Liu Jun has managed various funds, including the Huatai-PineBridge CSI 300 ETF since May 2012 [4]

Core Viewpoint - The announcement details the pledge and release of shares by the controlling shareholder of Haida Group, highlighting the specific numbers and percentages involved in these transactions [1][2]. Group 1: Share Pledge and Release Details - Haida Group's controlling shareholder, Haida Investment, pledged 4,500,000 shares, representing 0.49% of its holdings and 0.27% of the company's total shares, to Huatai Securities on June 12, 2024 [1]. - On September 12, 2024, Haida Investment supplemented the pledge with an additional 500,000 shares [2]. - The total pledged shares by Haida Investment amounted to 52,700,000 shares, which is 5.79% of its holdings and 3.17% of the company's total shares [2]. Group 2: Release of Pledged Shares - The total pledged shares were fully released on March 25, 2025 [2]. - As of the announcement date, Haida Investment held a total of 910,589,359 shares, accounting for 54.73% of the company [2].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 85.50 [7][8] Core Insights - The company achieved a revenue of RMB 28.66 billion in 2024, representing a year-on-year increase of 14.8%, and a net profit of RMB 6.24 billion, up 36.9% year-on-year, exceeding previous expectations [1][4] - The company has a strong international customer base and an integrated supply chain, which positions it well for long-term growth [1][4] - The company plans to continue its high-quality growth across all product categories, driven by increasing market demand and improved operational efficiency [2][4] Revenue Growth - The sports product sales increased by 9.8% to RMB 19.80 billion, driven by demand from China and the US [2] - The leisure product sales surged by 27.1% to RMB 7.21 billion, primarily due to increased demand from Japan and other regions [2] - The underwear product sales rose by 34.6% to RMB 1.44 billion, also driven by demand from Japan [2] Profitability and Cost Management - The gross margin improved by 3.8 percentage points to 28.1%, attributed to increased capacity utilization and operational efficiency [3] - The net profit margin increased by 3.5 percentage points to 21.8%, indicating a significant enhancement in profitability [3] - The overall expense ratio was well-managed, decreasing by 0.6 percentage points to 9.0% [3] Earnings Forecast and Valuation - The net profit estimates for 2025 and 2026 have been adjusted upwards by 3.4% and 4.6% to RMB 6.79 billion and RMB 7.75 billion, respectively [4] - The target price is based on a projected PE ratio of 17.4x for 2025, reflecting the company's growth potential and operational improvements [4]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 68.73 [7][24]. Core Insights - The company's Q4 revenue grew by 8.7% year-on-year to RMB 35.38 billion, aligning with consensus expectations of RMB 35.7 billion. The gross margin improved by 0.9 percentage points to 54%, and adjusted net profit increased by 13.3% year-on-year to RMB 4.7 billion, also meeting expectations [1][19]. - For 2025, total revenue is expected to rise by 11%, with advertising revenue and GMV growth slowing to 14% and 13% respectively, while adjusted net profit is projected to reach RMB 20.6 billion [1][20]. - The company is anticipated to accelerate revenue growth starting in Q2 2025, driven by AI commercialization opportunities in areas such as 2C subscriptions, 2B e-commerce advertising, and API calls, which could contribute an additional RMB 400-800 million in revenue [1][20]. Revenue and Profitability - Q4 e-commerce and other revenue growth slowed to 14.1%, below expectations by 3.5%. E-commerce GMV grew by 14.4% year-on-year, with a notable increase in the number of active merchants [2]. - The AI capabilities are expected to enhance advertising efficiency and optimize targeting, with Q4 advertising revenue growing by 13.3% year-on-year [3][14]. - The company has adjusted its revenue forecasts for 2025 and 2026, with a slight increase of 0.6% for 2025 and a minor decrease of 0.1% for 2026, while the adjusted net profit forecast for 2025 is revised down by 12.6% to RMB 20.6 billion [20][22]. Valuation and Market Position - The report introduces a new valuation for 2027, projecting revenue and adjusted net profit of RMB 163.8 billion and RMB 28.3 billion respectively. The target price has been raised to HKD 68.73 based on a sum-of-the-parts (SOTP) valuation approach [4][24]. - The valuation reflects a price-to-earnings (PE) ratio of 10.2 times for the advertising business, which is at a discount compared to comparable companies, indicating potential for growth as advertising efficiency improves with AI [24][25]. Business Segments - The "live streaming+" model continues to innovate, driving growth in traditional sectors, with significant increases in user engagement metrics for related services [12]. - The local lifestyle business saw GMV double year-on-year, with a 52.4% increase in monthly paying users, indicating strong demand and effective service optimization [13]. - The AI tool "可灵" has shown promising results in enhancing content creation and advertising efficiency, with significant revenue contributions expected from its commercialization efforts [14].

重要新闻 国家卫生健康委办公厅发布关于组织开展2025年人口高质量发展研究揭榜攻关活动的通知。 宁德时代25日晚间公告，收到中国证监会境外发行上市备案通知书， 宁德时代新能源科技股份有限公司正在申请发行境外上市外资股（H 股）并在香港联交 所主板挂牌上市。 重要的消息有哪些 申购提示 新股方面，中国瑞林申购代码732257，发行价20.52元/股，申购上限0.95万股。 投资有风险，申购需谨慎。 1.当地时间3月24日，美国总统特朗普表示，他将很快宣布针对汽车和药品的关税。此外，行业关税的征税对象还将包括木材和半导体行业。特朗普还表示，4月2日 的对等关税实施日将会如期实行，但会有国家有"折扣"。另据英国《金融时报》报道，特朗普着眼于4月2日出台两步走的关税计划，其中包括立即征收高达50%的 关税。 2.博鳌亚洲论坛25日发布《博鳌亚洲论坛亚洲经济前景及一体化进程2025年度报告》。报告预计，2025年亚洲加权实际GDP增长率为4.5%，略高于2024年的4.4%， 亚洲仍将成为世界经济的主要引擎。 3.外交部发言人郭嘉昆25日表示，中国将坚定不移推进高质量发展和高水平开放，欢迎各国企业把握机遇，投资中国，布 ...

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company achieved a revenue of 45.6 billion RMB in 2024, a year-on-year increase of 10%, with a net profit attributable to shareholders of 6.1 billion RMB, reflecting a 27% year-on-year growth [1] - The fourth quarter of 2024 saw a revenue of 13.4 billion RMB, with a quarter-on-quarter increase of 26% and a year-on-year increase of 4%, while the net profit attributable to shareholders reached 2.4 billion RMB, marking a 71% quarter-on-quarter increase [1] - The company is expected to continue its growth trajectory due to the advantages of ethane resources and the upcoming launch of new material projects [1] Summary by Sections Financial Performance - In 2024, the functional chemicals, polymer materials, and new energy materials segments generated revenues of 21.7 billion, 12 billion, and 800 million RMB, respectively, with year-on-year growth rates of 2%, 1%, and 81% [2] - The gross margins for these segments were 20%, 35%, and 22%, with respective year-on-year changes of +5%, +5%, and -15 percentage points [2] - The company’s net profit forecast for 2025-2027 is 7.4 billion, 8.6 billion, and 9.6 billion RMB, with corresponding EPS of 2.19, 2.56, and 2.86 RMB [5] Market Conditions - The prices of key products such as acrylic acid and its esters have shown positive trends, with average price increases of 11%, 13%, and 6% for acrylic acid, acrylic acid methyl ester, and acrylic acid butyl ester, respectively, since the beginning of 2025 [3] - The company benefits from low raw material prices, with the price of ethane remaining at a five-year low, which supports profitability in the C2 segment [3] Project Developments - The company is advancing its high-end new materials project, which includes a capacity of 1.7 million tons per year for high-end polyolefins and is expected to be completed by the end of 2025, with production starting in early 2026 [4]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 23.82 [8][9]. Core Insights - The company reported a revenue of RMB 12.261 billion for 2024, representing a year-on-year growth of 21.3%, and a net profit of RMB 4.372 billion, up 33.4% year-on-year. The revenue from innovative drugs reached RMB 9.477 billion, growing 38.1% year-on-year, and accounting for 74% of total revenue, which aligns with expectations [1][2]. - The growth in revenue is driven by strong performance in oncology and anti-infection segments, with revenues of RMB 8.122 billion and RMB 1.464 billion respectively, reflecting increases of 31.7% and 15.4% year-on-year. The gross margin improved to 91%, while the R&D expense ratio increased to 22%, indicating ongoing investment in innovation [2][3]. - The company has seven innovative drugs and nine indications included in the national medical insurance catalog as of 2024, with over 40 new molecular entities in more than 60 clinical trials. The company completed three license-in agreements in 2024, generating R&D expenses of RMB 247 million [3][4]. Summary by Sections Financial Performance - For 2024, the company achieved revenues of RMB 12.261 billion, with a year-on-year growth of 21.35%. The net profit for the same year was RMB 4.372 billion, reflecting a growth of 33.39% [7][19]. - The projected net profits for 2025 and 2026 are RMB 4.400 billion and RMB 4.179 billion respectively, with an expected EPS of RMB 0.74 for 2025 [5][19]. Research and Development - The company has a robust pipeline with 40 new molecular entities and over 60 clinical trials ongoing. Key drugs like Amatinib are expected to generate significant sales, projected to reach RMB 6 billion by 2025 [4][5]. - The company is actively expanding into autoimmune diseases and has multiple assets in development for skin diseases and kidney diseases [4][5]. Valuation - The company is valued at HKD 1,414 billion, with the innovative drug segment valued at HKD 1,378 billion and the generic drug segment at HKD 36 billion. The target price reflects an increase from the previous valuation of HKD 22.28 [5][9].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 237.90 RMB [8][9]. Core Views - The company reported a revenue of 3.026 billion RMB for 2024, a year-on-year increase of 5.45%, and a net profit attributable to the parent company of 1.958 billion RMB, also up by 5.33% year-on-year. However, the Q4 2024 revenue was 650 million RMB, down 7% year-on-year, and net profit was 372 million RMB, down 15% year-on-year, which was below previous expectations due to pressure on the medical aesthetics sector [1]. - The acquisition of 85% of Korean Regen Company for 190 million USD (approximately 1.386 billion RMB) is expected to inject performance momentum and boost market confidence. This marks the company's first overseas acquisition since its listing [1][4]. - Short-term recovery in the medical aesthetics sector may provide room for performance and valuation recovery, while long-term global resource integration and pipeline expansion are anticipated to create new growth trajectories [1]. Revenue and Profit Forecast - The company’s revenue is projected to grow to 3.643 billion RMB in 2025, representing a 20.41% increase, and net profit is expected to reach 2.398 billion RMB, a 22.52% increase. The EPS for 2025 is estimated at 7.93 RMB [5][7]. - The company’s estimated PE for 2025 is 30 times, with a target price of 237.90 RMB based on this valuation [5]. Product Performance - The revenue from gel products reached 1.216 billion RMB, growing by 5.01% year-on-year, driven mainly by the launch of new products. The solution category generated 1.744 billion RMB, with a stable growth of 4.4% year-on-year [2]. Regional Expansion - The company has significant expansion potential in regions such as North China, Central China, and South China, with North China showing a revenue increase of 33.21% year-on-year [3].